BioWorld

Sep. 24, 2009

View Archived Issues

Nexavar Continues to Wow in Breast Cancer Combo Study

The data just keep getting better for Nexavar in breast cancer. (BioWorld Today) Read More

No-Vote Panel: Exalgo Approval Needs Tight Abuse Safeguards

Direct RNA Sequencing May Get at 'True Transcriptome' of Cell

Pair of Phase III Trials Upcoming, Spectrum Adds $50M to Coffers

DxS Acquisition Boosts Qiagen's Companion Diagnostics Portfolio

Clinic Roundup

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...